Cargando…
Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients
AIM: To investigate whether a novel immune function biomarker QuantiFERON-Monitor (QFM) can identify cirrhotic patients at greatest risk of infection. METHODS: Adult cirrhotic patients on the liver transplant waiting list were recruited for this observational cohort study from a tertiary liver trans...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165271/ https://www.ncbi.nlm.nih.gov/pubmed/28050238 http://dx.doi.org/10.4254/wjh.v8.i35.1569 |
_version_ | 1782482801680973824 |
---|---|
author | Sood, Siddharth Yu, Lijia Visvanathan, Kumar Angus, Peter William Gow, Paul John Testro, Adam Gareth |
author_facet | Sood, Siddharth Yu, Lijia Visvanathan, Kumar Angus, Peter William Gow, Paul John Testro, Adam Gareth |
author_sort | Sood, Siddharth |
collection | PubMed |
description | AIM: To investigate whether a novel immune function biomarker QuantiFERON-Monitor (QFM) can identify cirrhotic patients at greatest risk of infection. METHODS: Adult cirrhotic patients on the liver transplant waiting list were recruited for this observational cohort study from a tertiary liver transplant referral unit. The immune function biomarker, QFM was performed using the same method as the widely available Quantiferon-gold assay, and measures output in interferon gamma in IU/mL after dual stimulation of the innate and adaptive immune systems. Ninety-one cirrhotic patients were recruited, with 47 (52%) transplanted on the day of their QFM. The remaining 44 (48%) were monitored for infections until transplant, death, or census date of 1(st) February 2014. RESULTS: Cirrhotic patients express a median QFM significantly lower than healthy controls (94.5 IU/mL vs 423 IU/mL), demonstrating that they are severely immunosuppressed. Several factors including model for end stage liver disease, presence of hepatocellular carcinoma, bilirubin, international normalized ratio and haemoglobin were associated with QFM on univariate analysis. Disease aetiology did not appear to impact QFM. On multivariate analysis, only Child-Pugh score and urea were significantly associated with a patient’s immune function as objectively measured by QFM. In the 44 patients who were not transplanted immediately after their blood test and could be monitored for subsequent infection risk, 13 (29.5%) experienced a pre-transplant infection a median 20 d (range 2-182) post-test. QFM < 214 IU/mL was associated with HR = 4.1 (P = 0.01) for infection. A very low QFM < 30 IU/mL was significantly associated (P = 0.003) with death in three patients who died while awaiting transplantation (HR = 56.6). CONCLUSION: QFM is lower in cirrhotics, allowing objective determinations of an individual’s unique level of immune dysfunction. Low QFM was associated with increased susceptibility to infection. |
format | Online Article Text |
id | pubmed-5165271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-51652712017-01-03 Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients Sood, Siddharth Yu, Lijia Visvanathan, Kumar Angus, Peter William Gow, Paul John Testro, Adam Gareth World J Hepatol Prospective Study AIM: To investigate whether a novel immune function biomarker QuantiFERON-Monitor (QFM) can identify cirrhotic patients at greatest risk of infection. METHODS: Adult cirrhotic patients on the liver transplant waiting list were recruited for this observational cohort study from a tertiary liver transplant referral unit. The immune function biomarker, QFM was performed using the same method as the widely available Quantiferon-gold assay, and measures output in interferon gamma in IU/mL after dual stimulation of the innate and adaptive immune systems. Ninety-one cirrhotic patients were recruited, with 47 (52%) transplanted on the day of their QFM. The remaining 44 (48%) were monitored for infections until transplant, death, or census date of 1(st) February 2014. RESULTS: Cirrhotic patients express a median QFM significantly lower than healthy controls (94.5 IU/mL vs 423 IU/mL), demonstrating that they are severely immunosuppressed. Several factors including model for end stage liver disease, presence of hepatocellular carcinoma, bilirubin, international normalized ratio and haemoglobin were associated with QFM on univariate analysis. Disease aetiology did not appear to impact QFM. On multivariate analysis, only Child-Pugh score and urea were significantly associated with a patient’s immune function as objectively measured by QFM. In the 44 patients who were not transplanted immediately after their blood test and could be monitored for subsequent infection risk, 13 (29.5%) experienced a pre-transplant infection a median 20 d (range 2-182) post-test. QFM < 214 IU/mL was associated with HR = 4.1 (P = 0.01) for infection. A very low QFM < 30 IU/mL was significantly associated (P = 0.003) with death in three patients who died while awaiting transplantation (HR = 56.6). CONCLUSION: QFM is lower in cirrhotics, allowing objective determinations of an individual’s unique level of immune dysfunction. Low QFM was associated with increased susceptibility to infection. Baishideng Publishing Group Inc 2016-12-18 2016-12-18 /pmc/articles/PMC5165271/ /pubmed/28050238 http://dx.doi.org/10.4254/wjh.v8.i35.1569 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Prospective Study Sood, Siddharth Yu, Lijia Visvanathan, Kumar Angus, Peter William Gow, Paul John Testro, Adam Gareth Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients |
title | Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients |
title_full | Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients |
title_fullStr | Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients |
title_full_unstemmed | Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients |
title_short | Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients |
title_sort | immune function biomarker quantiferon-monitor is associated with infection risk in cirrhotic patients |
topic | Prospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165271/ https://www.ncbi.nlm.nih.gov/pubmed/28050238 http://dx.doi.org/10.4254/wjh.v8.i35.1569 |
work_keys_str_mv | AT soodsiddharth immunefunctionbiomarkerquantiferonmonitorisassociatedwithinfectionriskincirrhoticpatients AT yulijia immunefunctionbiomarkerquantiferonmonitorisassociatedwithinfectionriskincirrhoticpatients AT visvanathankumar immunefunctionbiomarkerquantiferonmonitorisassociatedwithinfectionriskincirrhoticpatients AT anguspeterwilliam immunefunctionbiomarkerquantiferonmonitorisassociatedwithinfectionriskincirrhoticpatients AT gowpauljohn immunefunctionbiomarkerquantiferonmonitorisassociatedwithinfectionriskincirrhoticpatients AT testroadamgareth immunefunctionbiomarkerquantiferonmonitorisassociatedwithinfectionriskincirrhoticpatients |